Bayer Juggles a €3B Capital Injection with a Sweeping Legal Bid, Even as Farmers Turn on the Ag Giant

Bayer unleashed a flurry of strategic moves over the weekend that simultaneously strengthen its balance sheet, attack its biggest legal headache, and — in an ironic twist — alienate the very agricultural customers it needs to keep happy. The stock, already riding an 82% surge over the past year, now finds itself caught between a structural overhaul and a dangerous new source of friction.

Apollo Steps In with €3 Billion, but Bayer Keeps the Controls

The German conglomerate has brought Apollo Global Management aboard as a minority investor in a newly created company housing its long-acting contraceptive portfolio, which includes the Mirena and Kyleena brands. Apollo is injecting €3.0 billion in exchange for a non-controlling stake; Bayer retains majority ownership and full operational authority. The unit generated roughly €1.37 billion in revenue during fiscal 2025. The transaction is scheduled to close in the third quarter of 2026, providing an immediate boost to the company’s equity base without ceding control over one of its most profitable niches.

A Supreme Court Ruling Fuels a Mass Dismissal Bid

On the legal front, Bayer filed motions before US federal courts to dismiss approximately 4,000 bundled glyphosate lawsuits, leveraging a landmark Supreme Court decision handed down in late June. In Monsanto v. Durnell, the justices ruled 7–2 that federal law — specifically the FIFRA statute — preempts state-level claims requiring cancer warnings on glyphosate labels. Because the US Environmental Protection Agency has repeatedly classified glyphosate as non-carcinogenic and approved current label language, Bayer argues that the central legal foundation for thousands of pending cases now collapses.

Successfully dismissing these claims would mark a turning point for the company, which has been haunted by litigation risk since the $63 billion Monsanto acquisition in 2018. CEO Bill Anderson has also moved to isolate that risk structurally: Bayer’s entire US glyphosate business has been carved out into a new subsidiary called Ruveon LLC as part of a five-year plan for the Crop Science division. Industry observers see the separation as a possible prelude to a broader breakup, adding speculative fuel to the recent rally.

Should investors sell immediately? Or is it worth buying Bayer?

The August 19 Settlement Decision Looms

Investors are now awaiting a separate, pivotal court date. On August 19, 2026, a US judge is expected to issue a final ruling on Bayer’s proposed $7.25 billion class-action settlement covering current and future Roundup claims. If the court approves the deal and the dismissal motions gain traction, a major cloud of financial uncertainty could finally lift. Market participants are also watching for any early signals from federal judge Vincent Chhabria that he may be inclined to grant the dismissal requests.

An Unlikely Revolt: Farmers Turn on Bayer

Just as Bayer appeared to be gaining legal momentum, a backlash has erupted from an unexpected quarter. The very farming groups that stood with the company during the Supreme Court fight are now sharply criticizing it. The reason: Monsanto and Ruveon LLC have petitioned for steep anti-dumping tariffs — running between 69% and 446% — on Chinese glyphosate imports into the United States. Bayer argues that Chinese producers are flooding the market at unfair prices, but US farmers fear the tariffs will drive up their crop-protection costs at a time when margins are already tight. The dispute threatens to fray Bayer’s relationship with a core customer base for its Crop Science division.

Stock at a Technical Crossroads

Against this backdrop, the share price closed Friday at €50.18, up 31.97% year to date, 81.75% over twelve months, and 39.16% in the past 30 days alone. Yet the technical picture is flashing caution. The relative strength index sits at 70.4, placing the stock in overbought territory. The current price stands 33.18% above the 200-day moving average of €37.68, underscoring the ferocity of the rally, while annualized volatility remains elevated at 61.88% — unusually high for a DAX constituent. The 52-week high of €53.86, set on July 3, is now just 6.83% away.

Bayer reports second-quarter results on August 7. Between the court dates, the earnings print, and the mounting farmer discontent, the next few weeks will determine whether the combination of fresh capital and a judicial breakthrough can push the stock to fresh highs — or whether the rally has run ahead of reality.